» MDRNA Announces Phase 2 Trial Of PYY(3-36) Does Not Meet Weight Loss Endpoint
MDRNA, Inc. (Nasdaq: MRNA) announced results from a Phase 2 clinical trial evaluating PYY(3-36) Nasal Spray (PYY) for the treatment of obesity. The data indicate that PYY did not meet the primary…